• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home StudyGraphics

#VisualAbstract: Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

byMinjee Kim
March 24, 2023
in StudyGraphics
Reading Time: 3 mins read
#VisualAbstract: Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
Share on FacebookShare on TwitterShare on LinkedIn

1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo.

2. Secukinumab was well-tolerated, and the most common adverse effect was a headache.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hidradenitis suppurativa is an inflammatory dermatological condition that leads to abscesses and scarring of the skin. Current treatment typically includes topical medication and surgical intervention. There is only one biologic therapy (adalimumab) approved for the treatment of moderate-to-severe hidradenitis. The SUNSHINE and SUNRISE trials were two identical studies evaluating the use of subcutaneous secukinumab for the treatment of hidradenitis suppurativa. Participants were randomized to receive either placebo, secukinumab every two weeks or secukinumab every four weeks. The placebo-controlled study period was for 16 weeks, followed by a long-term treatment period without a placebo for 52 weeks. In both trials, significantly more patients on secukinumab every 2 weeks had a clinical response compared to placebo, and this benefit was sustained up to 52 weeks. The most common adverse effect in the secukinumab group was headaches and there were no treatment-related deaths. Limitations of this study include a shorter placebo-controlled period. Nevertheless, this study provides evidence for the clinical efficacy of secukinumab every 2 weeks for the treatment of hidradenitis suppurativa.

Click to read the study in The Lancet

RELATED REPORTS

Infection risk with infliximab (Remicade) and adalimumab (Humira) is similar in pediatric inflammatory bowel disease

Atopic dermatitis activity is not associated with cardiovascular risk

Relevant Reading: Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

In-Depth [randomized controlled trial]: SUNSHINE and SUNRISE were two identical trials conducted in 40 different countries. Eligible patients were 18 years old or older and had moderate-to-severe hidradenitis suppurativa for at least a period of a year. A total of 541 participants were randomized 1:1:1 to either secukinumab 300 mg every 2 weeks, secukinumab 300 mg every 4 weeks, or to placebo. The study consisted of a placebo-controlled period from week 0 to week 16 (period 1), a long-term treatment period to week 52 (period 2), and a follow-up period to week 60 (period 3). Treatments were given subcutaneously. At week 16, patients in the placebo group were randomly assigned to either secukinumab every two weeks or every four weeks. The primary outcome was the proportion of patients with clinical response, defined as a decrease in abscess and inflammatory nodule count by 50% or more with no increase in the number of abscesses or in the number of draining fistulae at week 16 compared with baseline.

The study contained 304 (56%) women and the mean age of participants was 36.1 years. Significantly more participants in the secukinumab every 2 weeks group had clinical response compared to placebo in both the SUNSHINE (34% in placebo, 45% in secukinumab every 2 weeks, odds ratio 1.8, p=0.0070) and SUNRISE trials (31% in placebo, 42% in secukinumab every 2 weeks, odds ratio 1.6, p=0.015). In the SUNRISE trial, there were significantly more patients with a clinical response on secukinumab every 4 weeks compared to placebo (odds ratio 1.9, p=0.0022); however, there was no significant difference in the SUNSHINE trial. The most common adverse effect in both the SUNSHINE and SUNRISE trial was a headache. There were no study-related deaths.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #HSadalimumabdermatologyHidradenitis suppurativainflammationSecukinumabskinskin abscessskin nodule
Previous Post

Patients with early pregnancy loss less likely to receive active management in the emergency department

Next Post

Spirituality may promote mental health recovery for people with schizophrenia in Southeast Asia

RelatedReports

Childhood IBD collage: a boy in a hooded sweatshirt beside a hot-water bottle in a knitted cover and a thermometer
Chronic Disease

Infection risk with infliximab (Remicade) and adalimumab (Humira) is similar in pediatric inflammatory bowel disease

July 14, 2026
Eczema more prevalent among older adults than previously thought
Cardiology

Atopic dermatitis activity is not associated with cardiovascular risk

April 2, 2026
Medicines in clinical trials collage: a plain white pharmacy bag with a folded top beside capsules and round tablets
All Specialties

Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

March 5, 2026
Inflammatory rheumatic disease collage: a calm woman in a knit wrap, a blank tablet, chamomile and an orange dot
Chronic Disease

C-reactive protein measurements may be misleading due to large within-person variability

January 13, 2026
Next Post

Spirituality may promote mental health recovery for people with schizophrenia in Southeast Asia

Cardiac arrest collage: an open defibrillator case with two pads, an engraved heart and a heartbeat spike line

72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
  • CDC reports 5,412 confirmed measles cases in the United States in 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.